Who
Claude Nicaise
Director
Company insider
Files Form 4 as: Director, Gain Therapeutics; Director, Sarepta Therapeutics; Director, Filana Therapeutics; Director, Chemomab Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $248K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 2 Jun 2015
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $144K10,500 at $13.71 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $144K6,780 at $21.23 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,500 at $0.00 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,500 at $0.00 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $144K10,500 at $13.71 | filing |
| 29 Jan 2026filed 29 Jan 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $144K6,780 at $21.23 | filing |
| 24 Jun 2025filed 25 Jun 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 23 May 2025filed 27 May 2025 | FLNA Filana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,500 at $0.00 | filing |
| 12 Mar 2025filed 13 Mar 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,746 at $0.00 | filing |
| 12 Mar 2025filed 13 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $245K9,746 at $25.18 | filing |
| 12 Mar 2025filed 13 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K2,491 at $99.64 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,792 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,383 | filing |
| 24 Jun 2024filed 26 Jun 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 May 2024filed 13 May 2024 | FLNA Filana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,679 at $0.00 | filing |
News
Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Claude Nicaise; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.